The legal setback centers on the '327 patent, which United Therapeutics successfully asserted against Yutrepia. The court’s decision creates significant uncertainty regarding the drug's future availability and may lead to the removal of its PH-ILD indication. While Liquidia CEO Roger Jeffs has signaled the company’s intent to appeal the ruling, the financial impact has already hit shareholders hard.

Liquidia reported Yutrepia sales of $300.3 million for the first half of 2026, a figure now overshadowed by the legal challenges and $69.1 million in non-cancelable supply commitments recorded in the company's second-quarter filings. The investigation, led by Levi & Korsinsky LLP under the SueWallSt banner, focuses on whether investors purchased shares at artificially inflated prices. Affected shareholders are being advised to document their purchase history and losses as legal counsel evaluates the viability of a securities class action suit.